Research
Swipe to view
Title : | Design and Synthesis of Rhabdopeptide/Xenortide-like peptides, and structurally diverse, hybrid sulfonamide and amide derivatives of amino acids, and their medicinal application |
Area of research : | Pharmaceutical Sciences |
Focus area : | Medicinal Chemistry, Peptide Science |
Principal Investigator : | Dr. Surendra Puri, Hemwati Nandan Bahuguna Garhwal University, Uttarakhand |
Timeline Start Year : | 2023 |
Timeline End Year : | 2025 |
Contact info : | puri[dot]surendrachem[at]gmail[dot]com |
Details
Swipe to view
Executive Summary : | Tuberculosis (TB), the most prevalent and deadly disease, is caused by Mycobacterium tuberculosis (MTB). The COVID-19 pandemic has increased the number of patients worldwide, with 10-6 million affected and 1-6 million dying from TB in 2021. The current treatment for TB is a combination of first-line drugs, which may lead to drug resistance. Currently, few compounds or lead molecules are in the TB drug pipeline. To fill this gap, researchers, scientists, and industry must collaborate to develop sustainable research and development programs. Several sulphonamide and amide derivatives have been reported for anti-TB activity. A comprehensive literature survey showed that the synthesis of Rhabdopeptide/Xenortide-like peptides and novel hybrid derivatives of sulfonamide and amide of amino acids have not been explored. In 2018, Lei et al. isolated Rhabdopeptide/Xenortide-like peptides from Xenorhabdus innexi DSM 16336, which showed promising activity against protozoan parasites. The amide and sulfonamide-containing molecules showed promising activity against TB bacteria. Some marked drugs like Pyrazinamide, Rifampicin, Viomycin, Sutezolid, and Golotimod showed the importance of amide functionalities. Hybrid derivatives of sulfonamide and amide of amino acid and their biological activities have been proposed. The Himalayas region is known for its biodiversity and medicinal plants, but they are underexplored due to inaccessibility. To fill this gap, isolation, characterization, and biological application of these medicinal plants will be carried out.Tuberculosis (TB), the most prevalent and deadly disease, is caused by Mycobacterium tuberculosis (MTB). The COVID-19 pandemic has increased the number of patients worldwide, with 10-6 million affected and 1-6 million dying from TB in 2021. The current treatment for TB is a combination of first-line drugs, which may lead to drug resistance. Currently, few compounds or lead molecules are in the TB drug pipeline. To fill this gap, researchers, scientists, and industry must collaborate to develop sustainable research and development programs. Several sulphonamide and amide derivatives have been reported for anti-TB activity. A comprehensive literature survey showed that the synthesis of Rhabdopeptide/Xenortide-like peptides and novel hybrid derivatives of sulfonamide and amide of amino acids have not been explored. In 2018, Lei et al. isolated Rhabdopeptide/Xenortide-like peptides from Xenorhabdus innexi DSM 16336, which showed promising activity against protozoan parasites. The amide and sulfonamide-containing molecules showed promising activity against TB bacteria. Some marked drugs like Pyrazinamide, Rifampicin, Viomycin, Sutezolid, and Golotimod showed the importance of amide functionalities. Hybrid derivatives of sulfonamide and amide of amino acid and their biological activities have been proposed. The Himalayas region is known for its biodiversity and medicinal plants, but they are underexplored due to inaccessibility. To fill this gap, isolation, characterization, and biological application of these medicinal plants will be carried out. |
Total Budget (INR): | 31,33,362 |
Organizations involved
Swipe to view
Implementing Agency : | Hemwati Nandan Bahuguna Garhwal University, Uttarakhand |
Funding Agency : | Anusandhan National Research Foundation/ Science and Engineering Research Board |
Source : | Anusandhan National Research Foundation/Science and Engineering Research Board (SERB), DST 2023-24 |